Drug intelligence / Profile preview

SKU-08

Development stage: Preclinical
Lead developer: Skye Biologics
Administration: Topical

Overview

SKU-08 is a biological therapeutic candidate developed by Skye Biologics, specifically designed for applications in general surgery to promote soft tissue repair and reduce the formation of post-operative adhesions. Part of Skye's "2nd Generation" platform, the product utilizes naturally advanced human biological materials to facilitate regenerative healing and provide a protective barrier during the recovery process. By minimizing internal scarring and adhesions, SKU-08 aims to improve surgical outcomes and reduce the risk of long-term complications associated with surgical procedures.

Beyond the preview

Go deeper on SKU-08.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKU-08.

Explore the full profile